Company Snapshot:
BridgeBio Pharma
BBIO is transitioning into a commercial-stage growth story, anchored by its breakthrough ATTR-CM therapy Attruby (acoramidis) and a deep genetic disease & oncology pipeline.
Key Catalysts:
Attruby Launch Off to a Strong Start 🚀
$36.7M in first full-quarter sales from 2,072 unique prescriptions
Pivotal data:
42% reduction in all-cause mortality
50% fewer cardiovascular hospitalizations over 30 months
Positions Attruby as a potential first-line standard of care in ATTR-CM.
Global Expansion in Motion 🌐
Regulatory approvals secured in Europe, Japan, and the UK.
Strategic launch partnership with Bayer to accelerate physician adoption and market penetration.
Smart Capital Strategy 💰
Secured $300M in non-recourse funding via partial monetization of European royalties.
Funds a strong commercial push while retaining long-term upside from BEYONTTRA™ sales.
Robust Pipeline Depth 🧬
Over 30 clinical and pre-clinical programs, offering multiple shots on goal beyond Attruby.
Investment Outlook:
Bullish Entry Zone: Above $38.00–$39.00
Upside Target: $60.00–$62.00, driven by blockbuster drug momentum, global rollout, and pipeline expansion.
📈 BBIO has the dual advantage of a de-risked lead asset and a rich R&D pipeline—positioning it for sustained multi-year growth.
#BBIO #Biotech #Pharma #ATTRCM #Cardiology #DrugLaunch #PipelineGrowth #BayerPartnership #GlobalExpansion #ClinicalTrials #GeneticDiseases #Pharmaceuticals
BridgeBio Pharma
BBIO is transitioning into a commercial-stage growth story, anchored by its breakthrough ATTR-CM therapy Attruby (acoramidis) and a deep genetic disease & oncology pipeline.Key Catalysts:
Attruby Launch Off to a Strong Start 🚀
$36.7M in first full-quarter sales from 2,072 unique prescriptions
Pivotal data:
42% reduction in all-cause mortality
50% fewer cardiovascular hospitalizations over 30 months
Positions Attruby as a potential first-line standard of care in ATTR-CM.
Global Expansion in Motion 🌐
Regulatory approvals secured in Europe, Japan, and the UK.
Strategic launch partnership with Bayer to accelerate physician adoption and market penetration.
Smart Capital Strategy 💰
Secured $300M in non-recourse funding via partial monetization of European royalties.
Funds a strong commercial push while retaining long-term upside from BEYONTTRA™ sales.
Robust Pipeline Depth 🧬
Over 30 clinical and pre-clinical programs, offering multiple shots on goal beyond Attruby.
Investment Outlook:
Bullish Entry Zone: Above $38.00–$39.00
Upside Target: $60.00–$62.00, driven by blockbuster drug momentum, global rollout, and pipeline expansion.
📈 BBIO has the dual advantage of a de-risked lead asset and a rich R&D pipeline—positioning it for sustained multi-year growth.
#BBIO #Biotech #Pharma #ATTRCM #Cardiology #DrugLaunch #PipelineGrowth #BayerPartnership #GlobalExpansion #ClinicalTrials #GeneticDiseases #Pharmaceuticals
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.
Pernyataan Penyangkalan
Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.